ProQR Therapeutics N.V (PRQR) Income towards Parent Company: 2021-2025
Historic Income towards Parent Company for ProQR Therapeutics N.V (PRQR) over the last 5 years, with Sep 2025 value amounting to -$12.9 million.
- ProQR Therapeutics N.V's Income towards Parent Company fell 38.37% to -$12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$48.3 million, marking a year-over-year decrease of 86.78%. This contributed to the annual value of -$29.7 million for FY2024, which is 2.46% up from last year.
- According to the latest figures from Q3 2025, ProQR Therapeutics N.V's Income towards Parent Company is -$12.9 million, which was up 11.43% from -$14.6 million recorded in Q2 2025.
- Over the past 5 years, ProQR Therapeutics N.V's Income towards Parent Company peaked at -$2.9 million during Q2 2024, and registered a low of -$23.5 million during Q3 2022.
- Moreover, its 3-year median value for Income towards Parent Company was -$9.3 million (2024), whereas its average is -$9.0 million.
- As far as peak fluctuations go, ProQR Therapeutics N.V's Income towards Parent Company surged by 72.01% in 2023, and later plummeted by 402.18% in 2025.
- Quarterly analysis of 5 years shows ProQR Therapeutics N.V's Income towards Parent Company stood at -$20.8 million in 2021, then spiked by 34.92% to -$13.6 million in 2022, then spiked by 60.85% to -$5.3 million in 2023, then crashed by 85.19% to -$9.8 million in 2024, then plummeted by 38.37% to -$12.9 million in 2025.
- Its last three reported values are -$12.9 million in Q3 2025, -$14.6 million for Q2 2025, and -$11.0 million during Q1 2025.